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Summary
Background Dupilumab (monoclonal antibody inhibiting IL-4/IL-13 signalling) is
approved for use in adolescents aged ≥ 12 years with inadequately controlled
moderate-to-severe atopic dermatitis (AD). Dupilumab significantly improved AD
signs/symptoms in a 16-week, randomised, placebo-controlled phase III trial in
adolescents (NCT03054428).
Objectives To characterize the pharmacokinetics of dupilumab, and long-term
safety and efficacy in adolescents.
Methods This was a global, multicentre, phase IIa, open-label, ascending-dose,
sequential cohort study with a phase III open-label extension (OLE) in adoles-
cents with moderate-to-severe AD. In the phase IIa study, patients received one
dupilumab dose (2 mg kg1 or 4 mg kg1) and 8 weeks of pharmacokinetic
sampling. Thereafter, patients received the same dose weekly for 4 weeks, with
8-week safety follow-up. Patients then enrolled in the OLE, continuing 2 mg
kg1 or 4 mg kg1 dupilumab weekly. Primary end points were dupilumab con-
centration–time profile and incidence of treatment-emergent adverse events
(TEAEs). Secondary outcomes included Eczema Area and Severity Index (EASI).
Results Forty adolescents received dupilumab in the phase IIa study; 36 enrolled in
the OLE. Dupilumab showed nonlinear, target-mediated pharmacokinetics. Mean
 SD trough dupilumab concentrations in serum at week 48 (OLE) were 74  19
mg L1 and 161  60 mg L1 for 2 mg kg1 and 4 mg kg1, respectively. Dupilu-
mab was well tolerated over 52 weeks; the most common TEAEs were nasopharyn-
gitis (week 52: 41% [2 mg kg1], 47% [4 mg kg1]) and AD exacerbation (29%,
42%). After one dupilumab dose in the phase IIa study, EASI improved from base-
line to week 2 [mean  SD reduction 34%  20% (2 mg kg1) and 51% 
29% (4 mg kg1)]. With continuing treatment, EASI scores improved further
[week 52: 85%  12% (2 mg kg1) and 84%  20% (4 mg kg1)].
Conclusions In adolescents with moderate-to-severe AD, dupilumab’s pharmacoki-
netic profile was similar to that in adults. These 52-week safety and efficacy data
support long-term use of dupilumab in this patient population.
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What’s already known about this topic?
• Adolescents with moderate-to-severe atopic dermatitis (AD) have high unmet med-
ical need, with significant disease burden and limited treatment options.
• Dupilumab (monoclonal antibody against interleukin-4 receptor a) is approved for
the treatment of adolescents with moderate-to-severe AD who are inadequately
responsive to standard of care (U.S.A.) or candidates for systemic therapy (Euro-
pean Union).
• A 16-week, randomized, placebo-controlled phase III trial in adolescents demon-
strated significant improvements in AD signs/symptoms with an acceptable safety
profile.
What does this study add?
• These studies demonstrate the long-term safety and efficacy of dupilumab in ado-
lescents with moderate-to-severe AD for up to 52 weeks of treatment, thus extend-
ing and reinforcing the findings from the 16-week dupilumab phase III trial.
• The data from these studies also support the use of dupilumab in combination
with current standard of care (topical corticosteroids), which was not evaluated in
the 16-week phase III monotherapy trial.
Atopic dermatitis (AD) is a chronic inflammatory skin condi-
tion characterized by pruritus, disruption of skin barrier func-
tion and type 2 inflammation.1 The worldwide prevalence of
AD in adolescents is estimated to be 02–246%.2,3 AD has
substantial detrimental effects on health-related quality of life
(QoL). Adolescents with AD have a high prevalence of depres-
sion, anxiety and attention deficit–hyperactivity disorder,4,5
and a greater risk of developing asthma, allergic rhinitis and
food allergy,6–9 which typically persist into adulthood.7,10
Until recently, approved medications for adolescents with AD
were limited to topical therapies, including topical corticos-
teroids (TCS) and topical calcineurin inhibitors (TCIs); how-
ever, their long-term application is limited by adherence and
risk of side-effects.1,11 Although systemic immunosuppressive
agents are not approved for use in adolescents with AD (ex-
cept for systemic corticosteroids and ciclosporin in patients
aged ≥ 16 years in certain countries), they are sometimes used
off label for severe AD refractory to topical therapy. Systemic
immunosuppressive agents, such as azathioprine, methotrexate
and mycophenolate, are only recommended for short-term
use owing to risk of infections, malignancies, and hepatic,
renal and haematological toxicities.12–14 Consequently, there is
still an overall unmet need for safe and effective treatments
for adolescents with moderate-to-severe AD.
Dupilumab is a fully human VelocImmune-derived15,16
monoclonal antibody that blocks the shared receptor compo-
nent for interleukin (IL)-4 and IL-13, thus inhibiting sig-
nalling of both IL-4 and IL-13. In randomized trials of adults
with moderate-to-severe AD inadequately controlled with
topical therapies, dupilumab had a favourable benefit-to-risk
safety profile, improved disease severity and symptoms, and
improved scores for anxiety, depression and QoL.17–21 Positive
outcomes have also been reported in asthma, chronic sinusitis
with nasal polyps and eosinophilic oesophagitis, highlighting
the importance of IL-4/IL-13 as drivers of multiple type 2
inflammatory diseases.22–28 Dupilumab is approved for subcu-
taneous administration in the treatment of patients aged ≥ 12
years (400 mg loading dose followed by 200 mg every 2
weeks in adolescents aged ≥ 12 to < 18 years with a baseline
body weight of < 60 kg, or 600 mg loading dose followed by
300 mg every 2 weeks for adolescents with a baseline body
weight of ≥ 60 kg) in the U.S.A. with moderate-to-severe AD
inadequately controlled with topical prescription therapies or
when those therapies are not advisable;29 in Japan for the
treatment of adult patients with AD not adequately controlled
with existing therapies; and in the European Union for use in
patients aged ≥ 12 years with moderate-to-severe AD who are
candidates for systemic therapy.30 Dupilumab is also approved
for certain patients with other type 2 inflammatory diseases,
including asthma and chronic rhinosinusitis with nasal polyps,
in a number of countries.23,24,26–29
We present the results of two studies evaluating dupilumab
in adolescents with moderate-to-severe AD, with the objectives
to investigate the pharmacokinetic (PK) profile, safety and effi-
cacy of dupilumab (phase IIa study), and its long-term safety
and efficacy [ongoing phase III open-label extension (OLE)].
Materials and methods
Study design and patient selection
The first study, a phase IIa, multicentre, open-label, ascend-
ing-dose, sequential cohort study (R668-AD-1412;
NCT02407756), was conducted at multiple centres in Europe
(Czech Republic, Hungary, Germany, Poland, the U.K.) and
Canada. The study consisted of a screening period of up to 35
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days, a baseline visit and two treatment phases: in part A,
patients received a single dose of dupilumab followed by an
8-week sampling period for systemic drug concentration; in
part B, patients received four weekly doses followed by an
8-week safety follow-up period (Figs S1 and S2; see Supporting
Information). Patients were required to discontinue systemic
treatments for AD (oral corticosteroids and non-steroidal
immunosuppressants) for at least 2 weeks prior to the baseline
visit. In addition, patients who did not complete part A per
schedule, for example patients who received systemic corticos-
teroids or systemic nonsteroidal immunosuppressive agents as
rescue treatment within 2 weeks of the scheduled start of the
repeat dose, had a 2-week washout period of the rescue
medication prior to starting part B of the study.
The second study, an ongoing phase III OLE (R668-AD-
1434 LIBERTY AD PED-OLE; NCT02612454) enrolling paedi-
atric patients who participated in previous dupilumab AD trials
[the present phase IIa study, and phase III (NCT03054428)
and phase I (NCT03050151) studies], includes centres from
Canada, the Czech Republic, Germany, Hungary, Poland, the
U.K. and the U.S.A. The study consists of a screening period
(day 28 to day 1), a treatment period that lasts until regu-
latory approval of the product for the age group of the
patients in their geographical region, and a 12-week follow-
up period (Fig. S2). Patients were required to discontinue sys-
temic treatments for AD (oral corticosteroids and nonsteroidal
immunosuppressants) for at least 2 weeks prior to the baseline
visit.
The patients selected for enrolment in the phase IIa and
phase III OLE study included paediatric patients (aged ≥ 6
to < 18 years) with AD that was inadequately controlled
with topical medications or for whom topical therapies
were inadvisable. Eligible patients had AD for > 1 year
before screening, based on American Academy of Dermatol-
ogy criteria;1 a baseline Investigator Global Assessment
(IGA) of 3 or 4; and ≥ 10% of their body surface area
(BSA) affected by AD. Patients who had a serious adverse
event (SAE) deemed related to the study drug, or an
adverse event (AE) related to the study drug and which led
to discontinuation from the study, were excluded from the
OLE. See Appendix S2 for full eligibility criteria (see Sup-
porting Information).
The phase IIa and OLE data presented herein only include
adolescents aged ≥ 12 to < 18 years with AD who had partici-
pated in the phase IIa study and continued into the OLE study.
Both studies were conducted in accordance with the princi-
ples established in the Declaration of Helsinki and the Interna-
tional Conference on Harmonisation guidelines for Good
Clinical Practice. All study documents and procedures were
approved by the appropriate institutional review boards/ethics
committees at each study centre (Table S1; see Supporting
Information). Assent and written informed consent were pro-
vided by the patients (as appropriate) and their parents or
legal guardians. An independent data monitoring committee
monitored patient safety.
Randomization and procedures
Patients received a single subcutaneous (SC) dose of 2 mg
kg1 or 4 mg kg1 dupilumab on day 1, and blood samples
were collected for 8 weeks to characterize the single-dose PK
profile (part A). Patients then received four weekly doses of
dupilumab and were followed for 8 weeks for safety evalua-
tion (part B). To minimize the volume of blood sample col-
lection and reduce the number of blood draws needed to
acquire informative dupilumab concentration data, patients in
part A were randomized to one of three semi-dense PK
sampling schedules: days 2, 15, 36 and 57; days 4, 22, 43
and 57; or days 8, 29, 50 and 57. Dupilumab concentra-
tions were assessed using a validated enzyme-linked
immunosorbent assay, the lower limit of quantitation of
which is 0078 mg L1.
In the phase III OLE, patients aged ≥ 12 to < 18 years
received 2 mg kg1 or 4 mg kg1 dupilumab SC weekly (up
to a maximum of 300 mg).
Rescue medication was permitted in both studies at the
investigator’s discretion if medically necessary to control intol-
erable AD symptoms. See Appendix S2 for detailed descrip-
tions of rescue treatments, prohibited medications and
procedures.
Outcome measures
In the phase IIa study, the primary outcome was the character-
ization of the PK of dupilumab. The PK profile was assessed
by integrating the full complement of sampling schedules to
construct a single complete mean concentration–time profile
for each group (na€ıve pooling). Secondary outcomes were
assessed from baseline to week 20 (part B, week 12) and
included incidence of AEs; percentage change from baseline in
Eczema Area and Severity Index (EASI), Peak Pruritus Numeri-
cal Rating Scale (NRS) and SCORing Atopic Dermatitis
(SCORAD); the proportion of patients achieving an IGA of 0
or 1 (clear or almost clear); and change from baseline in per-
centage of BSA (%BSA) affected by AD.
In the phase III OLE, the primary outcomes were incidence
(%) and rate (events per patient year) of AEs. Secondary out-
comes included incidence and rate of SAEs, AEs of special
interest and efficacy up to week 52. See Appendix S2 in Sup-
porting Information, for a full list of end points.
Pharmacokinetic analyses
PK analyses were conducted from the mean concentration–
time profiles after integration of the three semi-dense sam-
pling schedules. Mean peak dupilumab concentration in serum
(Cmax) and time to maximum mean concentration (tmax) were
recorded. The area under the concentration–time curve from
time zero to the time of last positive concentration (AUClast,
determined prior to the last mean concentration assessed at
week 8) was calculated using the linear–trapezoidal rule using
Phoenix WinNonlin (version 63; Certara, USA, Inc.,
© 2019 The Authors. British Journal of Dermatology
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Princeton, NJ, U.S.A.). Cmax and tmax were determined by
visual inspection of the mean concentration–time profile.
Statistical analyses
No formal sample size or power calculations were per-
formed. PK, safety and efficacy variables were summarized
descriptively. Furthermore, no inferential statistical tests were
prespecified in the statistical analysis plan to allow compar-
ison between the two treatment arms. Any differences
observed in the descriptive summary of the PK, safety and
efficacy variables were based on numerical comparisons. The
analysis set for all statistical analyses for both studies
included all patients who received any study drug. Patients
in the PK population had to have ≥ 1 nonmissing functional
dupilumab result following the first dose of the study drug.
If a PK drug concentration was missing, data were set to
missing and only observed data were used. Data after rescue
treatment use during part B of the phase IIa study were set to
missing. Missing values during the first 4-week repeat-dose
treatment period of part B up to the end-of-treatment visit
were imputed by the last-observation-carried-forward method.
After the end of treatment in part B, no missing data imputa-
tion was made. For the phase III open-label extension, an all-
observed method was employed, regardless of whether rescue
treatment was used or if data were collected after withdrawal
from study treatment. No missing values were imputed. SAS
version 92 (SAS Institute Inc., Cary, NC, U.S.A.) was used for
all analyses.
Results
Patients
Of the 88 paediatric patients screened for the phase IIa study,
78 (89%) were enrolled, including 40 adolescents (Fig. S3;
see Supporting Information). Two adolescents did not com-
plete the study treatment, one in the cohort receiving 2 mg
kg1 dupilumab (due to receiving a rabies vaccination) and
one in the cohort receiving 4 mg kg1 dupilumab (due to
needle phobia). A total of 36 adolescents (including three
younger patients from the phase IIa study who reached the
age of 12 years at the time rolling over to OLE) continued to
the phase III OLE, and 34 completed ≥ 52 weeks of treatment
with 2 mg kg1 or 4 mg kg1 dupilumab weekly. Two
patients did not complete the OLE study: one was lost to fol-
low-up and one withdrew consent (Fig. S3).
Mean  SD age was 15  2 years and 14  2 years in the
2 mg kg1 and 4 mg kg1 groups, respectively, and mean
duration of AD was 12 and 13 years, respectively (Table 1).
At baseline in the phase IIa study, mean  SD EASI was 35 
17 and 29  15 in the 2 mg kg1 and 4 mg kg1 groups,
respectively, and 26  17 and 21  18 at baseline of the
OLE. Most patients had moderate-to-severe pruritus and exten-
sive involvement of their skin surface at the phase IIa baseline.
A total of 35% (2 mg kg1) and 30% (4 mg kg1) of patients
had received noncorticosteroid immunosuppressants prior to
baseline of the phase IIa study, including ciclosporin or aza-
thioprine, and 25% and 20%, respectively, did not respond to
noncorticosteroid immunosuppressants. Most patients had
other concomitant atopic/allergic diseases, including asthma,
allergic rhinitis and food allergies.
Pharmacokinetics
After a single dose, mean  SD Cmax was 10  2 mg L1 and 23
 9 mg L1 for the 2 mg kg1 and 4 mg kg1 dupilumab dose
groups, respectively; tmax was 4–8 days (Fig. 1 and Fig. S4; see
Supporting Information). After pooling of the single-dose con-
centration data, the estimated AUClast (based on the mean pro-
file) was 104 day 9 mg L1 and 362 day 9 mg L1 in the 2
mg kg1 and 4 mg kg1 groups, respectively. In the OLE, mean
dupilumab concentrations increased in a slightly greater-than-
dose-proportional manner from baseline to week 48 between
the 2 mg kg1 and 4 mg kg1 regimens, achieving mean  SD
trough dupilumab concentrations in serum (Ctrough) of 74  19
mg L1 and 161  60 mg L1, respectively (Figs 1 and S4).
Safety
In the phase IIa study, 50% and 65% of patients in the 2 mg
kg1 and 4 mg kg1 dupilumab groups experienced one or
more treatment-emergent adverse events (TEAEs) during part A,
respectively, and 40% and 55% during part B (Table 2). Two
SAEs were reported in each dose group: a 17-year-old patient in
the 2 mg kg1 group presented with palpitations and infected
AD, and a 13-year-old patient in the 4 mg kg1 group reported
staphylococcal skin infection and infected AD (Table 3). None
of the SAEs was considered related to study treatment, and no
TEAEs led to permanent study drug discontinuation. The most
frequent TEAEs were nasopharyngitis and AD exacerbation (dur-
ing the period when dupilumab was not being administered).
Incidences of skin infections were low; injection-site reactions
were mild and occurred in one patient per group (Table 3). No
conjunctivitis events were reported (Table 3).
In the OLE, nearly all adolescents reported one or more
TEAE (Table 2). Three patients experienced an SAE (patent
ductus arteriosus, food allergy and ankle fracture), which were
not considered related to study treatment. No TEAEs led to
permanent treatment discontinuation. The most common
TEAEs in this study were nasopharyngitis and AD exacerbation
(Table 3). The incidence of skin infections was 29% and 42%
for the 2 mg kg1 and 4 mg kg–1 arms, respectively. Injec-
tion-site reactions occurred in 18% and 11% of patients,
respectively, but most of these events were mild in intensity.
Conjunctivitis was reported in 18% and 16% of patients in the
2 mg kg1 and 4 mg kg1 dose groups, respectively. No con-
junctivitis events were serious, and all cases recovered/re-
solved during the treatment period. TEAEs of special interest
included suicidal behaviour, and systemic or severe hypersen-
sitivity, and were reported for one patient each in the 2 mg
kg1 group. No deaths were reported in either study.
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Efficacy
By week 2 of the phase IIa study, EASI decreased by a mean  SD
of 34%  20% and 51%  29% after a single dose of 2 mg
kg1 and 4 mg kg1 dupilumab, respectively (Table 4, Fig. 2a).
Improvements in EASI were maintained up to week 52, with a
mean  SD reduction of 85%  12% and 84%  20% for
the 2 mg kg1 and 4 mg kg1 groups, respectively (Table 4,
Fig. 2a, Figs S5a and S6a; see Supporting Information).
The proportion of adolescents achieving EASI-50 (≥ 50%
improvement from baseline in EASI) at week 12 was 70% in
the 2 mg kg1 group and 75% in the 4 mg kg1 group,
increasing in the OLE to 100% and 89%, respectively, at
week 52 (Table 4, Fig. 2b). EASI-75 (≥ 75% improvement
from baseline in EASI) was achieved by 55% and 40% of
patients in the 2 mg kg1 and 4 mg kg1 groups, respec-
tively, at week 12, increasing in the OLE to 88% and 78%,
respectively, at week 52 (Table 4, Fig. 2c). The proportion of
patients with IGA 0 or 1 at week 12 was 10% in the 2 mg
kg1 group and 35% in the 4 mg kg1 group, increasing to
38% and 44%, respectively, at week 52 of the OLE (Table 4,
Fig. 2d).
Table 1 Baseline demographics and disease characteristics
Phase IIa study Phase III OLE
Dupilumab
2 mg kg1 (n = 20)
Dupilumab
4 mg kg1 (n = 20)
Dupilumab
2 mg kg1 (n = 17)
Dupilumab
4 mg kg1 (n = 19)
Mean  SD age (years) 15  2 14  2 15  2 14  2
Male sex 9 (45) 9 (45) 6 (35) 11 (58)
Mean  SD weight (kg) 53  12 56  13 53  10 57  14
Mean  SD BMI (kg m2) 20  3 22  4 20  3 22  4
Mean  SD duration of AD (years) 12  4 13  2 12  4 13  2
Mean  SD EASIa 35  17 29  15 26  17 21  18
IGAb
4 12 (60) 9 (45) 5 (29) 4 (21)
3 8 (40) 11 (55) 11 (65) 11 (58)
2 0 0 1 (6) 4 (21)
Mean  SD SCORADc 68  13 63  14 56  17 54  24
Mean  SD Peak Pruritus NRSd 6  2 7  2 5  2 5  3
Mean  SD %BSA affected 52  25 46  25 40  26 37  27
Mean  SD POEMe NA NA 15  7 16  8
Mean  SD CDLQIf NA NA 9  5 9  8
Any previous noncorticosteroid
immunosuppressants
7 (35)a 6 (30)g 4 (24)g 3 (16)g
No response to previous
noncorticosteroid immunosuppressants
5 (25)g 4 (20)g NA NA
Any other atopic conditionh 15 (75) 15 (75) 15 (88) 15 (79)
Allergic rhinitis 9 (45) 8 (40) 10 (59) 9 (47)
Food allergy 7 (35) 10 (50) 8 (47) 11 (58)
Asthma 6 (30) 9 (45) 7 (41) 8 (42)
Allergic conjunctivitis 5 (25) 7 (35) 6 (35) 7 (37)
Chronic rhinosinusitis 0 3 (15) 0 3 (16)
Urticaria 1 (5) 1 (5) 1 (6) 1 (5)
Other allergies 11 (55) 13 (65) 11 (65) 14 (74)
Data are n (%) unless otherwise indicated. OLE, open-label extension; BMI, body mass index; AD, atopic dermatitis; EASI, Eczema Area and
Severity Index; IGA, Investigator’s Global Assessment; SCORAD, SCORing Atopic Dermatitis; NRS, Numerical Rating Scale; BSA, body surface
area; POEM, Patient Oriented Eczema Measure; NA, not applicable; CDLQI, Children’s Dermatology Life Quality Index. aScores on the EASI
range from 0 to 72, with higher scores indicating greater severity; a change of 66 has been estimated to be the clinically meaningful
within-person change or response definition. bScores on the IGA scale range from 0 to 4, with higher scores indicating greater severity; the
clinically meaningful within-person change or response definition for this scale has not been determined. cSCORAD is a combined score of
investigator-reported disease severity and affected BSA and patient-reported symptoms of itch and sleep loss; scores range from 0 to 103,
with higher scores indicating greater severity. A change of 87 has been estimated as the clinically meaningful within-person change or
response definition. dThe peak score on the NRS for pruritus is a patient-reported measure that assesses the maximum itch intensity in the
previous 24 h on a scale ranging from 0 to 10, with higher values indicating worse itching. The clinically meaningful within-person change
or response definition is 4 points. eThe POEM, a composite measure of patient-reported symptoms, including the effect of symptoms on
sleep, evaluates the frequency of symptoms (including itching) and the effect of AD on sleep on a scale of 0 to 28, with higher scores indi-
cating greater severity; the clinically meaningful within-person change or response definition is 6 points. fThe CDLQI evaluates health-related
quality of life (QoL) on a scale of 0 to 30, with higher scores indicating greater impact on QoL. The clinically meaningful within-person
change or response definition is 6 points. gIncludes azathioprine and ciclosporin. hExcludes AD.
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Fig 1. Mean log-scaled concentrations of dupilumab in serum vs. nominal time. (a) Concentration–time profile of the phase IIa study. Vertical
arrows represent time points at which dupilumab 2 mg kg1 or 4 mg kg1 was administered. (b) Concentration–time profile of the phase III
open-label extension (OLE). Patients in the OLE received dupilumab 2 mg kg1 weekly or 4 mg kg1 weekly. Linear-scale concentration–time
profiles and patient numbers are shown in Figure S4 (see Supporting Information). LLOQ, lower limit of concentration.
Table 2 Overview of treatment-emergent adverse events (TEAEs)
Phase IIa study Phase III OLEa
Dupilumab
2 mg kg1
(n = 20)
Dupilumab
4 mg kg1
(n = 20)
Dupilumab
2 mg kg1
(n = 17)
Dupilumab
4 mg kg1
(n = 19)
Dupilumab
2 mg kg1
(n = 17)
Dupilumab
4 mg kg1
(n = 19)Part A Part B Part A Part B
TEAEs n n nE/100 PYb
Total TEAEs 19 16 40 31 161 253 485 718
Total serious TEAEs 1 1 1 1 3 0 9 0
Total TEAEs related
to treatment
0 2 6 5 6 19 18 54
Total TEAEs related
to permanent
treatment discontinuation
0 0 0 0 0 0 0 0
Patients with TEAEs n (%) n (%) nP/100 PYc
Any TEAE 10 (50) 8 (40) 13 (65) 11 (55) 17 (100) 18 (95) 331 267
Any serious TEAE 1 (5) 1 (5) 1 (5) 1 (5) 3 (18) 0 10 0
TEAEs related to treatment 0 1 (5) 2 (10) 3 (15) 5 (29) 5 (26) 19 17
TEAEs leading to
discontinuation
0 0 0 0 0 0 0 0
OLE, open-label extension; nE/100 PY, number of events per 100 patient years; nP/100PY, number of patients with ≥ 1 event per 100
patient years. aIncludes all TEAEs reported up to the first visit when patients switched from weight-based dosing (2 mg kg1 or 4 mg kg1)
to a fixed dose regimen of 300 mg every 4 weeks. bThe TEAE rate per PY was defined as the number of TEAEs divided by total PY in the
TEAE period; the total PY was calculated as the sum of duration of the TEAE period in the OLE for all patients. cThe number of patients with
≥ 1 TEAE per PY was defined as the number of patients with ≥ 1 TEAE divided by total PY among patients in the study and at risk of an
initial occurrence of the event; for patients with an event, the number of PY was calculated up to the date of the first event; for patients
without an event, it corresponded to the duration of the TEAE period.
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The mean  SD reduction in Peak Pruritus NRS from
baseline to week 12 was 31%  68% and 38%  34%
for the 2 mg kg1 and the 4 mg kg1 groups, respectively,
and 68%  22% and 66%  25% by week 52
(Table 5, Fig. 2e). The proportions of patients who
achieved ≥ 3 point improvement in Peak Pruritus NRS at
week 12 of the phase IIa and week 52 of the phase III
OLE, respectively, were 50% and 75%, respectively, for the
2 mg kg1 group and 45% and 78%, respectively, for the
4 mg kg1 group (Table 5, Fig. 2f). A ≥ 4 point improve-
ment in Peak Pruritus NRS was achieved by 40% of adoles-
cents in both treatment groups at week 12 and increased to
69% for the 2 mg kg1 group and 72% for the 4 mg
kg1 group at week 52 (Table 5).
Sustained improvements were also seen in EASI-90 (≥ 90%
improvement from baseline in EASI), SCORAD and %BSA in both
studies (Tables 4 and 5, Figs. S5b and S6b,c). Moreover, the fre-
quency of symptoms and QoL, as assessed by the Patient
Oriented Eczema Measure and Children’s Dermatology Life
Quality Index, respectively, in the OLE, showed improvements
by week 12, which were maintained up to week 52 (Fig. S6d,e).
Concomitant medication
Overall, 85% and 65% of patients in the 2 mg kg1 and 4 mg
kg1 dupilumab groups of the phase IIa study, respectively,
used TCS as concomitant medication (Table S2; see Supporting
Information). The most commonly used TCS in both treat-
ment arms was potent (group III). TCIs were used by 55%
and 30% of adolescents in the 2 mg kg1 and 4 mg kg1
groups, respectively.
In the OLE, 65% and 74% of adolescents in the 2 mg kg1
and 4 mg kg1 groups, respectively, used TCS, with most
using potent (group III) TCS (Table S2). TCI use was 41%
and 16% in the in the 2 mg kg1 and 4 mg kg1 groups,
respectively.
Table 3 Treatment-emergent adverse event (TEAE) profile
Phase IIa study Phase III OLEa
Dupilumab
2 mg kg1 (n = 20)
Dupilumab
4 mg kg1 (n = 20)
Dupilumab 2
mg kg1
(n = 17)
Dupilumab
4 mg kg1
(n = 19)
Dupilumab
2 mg kg1
(n = 17)
Dupilumab
4 mg kg1
(n = 19)Part A Part B Part A Part B
Patients with TEAEs n (%) n (%) nP/100 PYb
Any infection (SOC) 3 (15) 4 (20) 8 (40) 6 (30) 14 (82) 17 (89) 100 136
Skin infection 0 1 (5) 3 (15) 3 (15) 5 (29) 8 (42) 18 34
Nonherpetic skin infectionsc 0 1 (5) 3 (15) 3 (15) 3 (18) 4 (21) 10 13
Herpes viral infections (HLT)d 0 0 1 (5) 1 (5) 3 (18) 4 (21) 10 14
Injection-site reactions (HLT)e 0 1 (5) 1 (5) 0 3 (18) 2 (11) 10 6
Conjunctivitisf 0 0 0 0 3 (18) 3 (16) 10 9
Most common TEAEs (PT)g
Nasopharyngitis 1 (5) 2 (10) 6 (30) 4 (20) 7 (41) 9 (47) 28 37
Dermatitis atopic 2 (10) 0 3 (15) 1 (5) 5 (29) 8 (42) 18 27
Headache 1 (5) 1 (5) 0 1 (5) 6 (35) 5 (26) 24 16
Oropharyngeal pain 0 1 (5) 0 0 4 (24) 5 (26) 14 16
Tonsillitis 0 0 0 0 1 (6) 5 (26) 3 16
URTI 1 (5) 1 (5) 1 (5) 0 4 (24) 4 (21) 13 13
Diarrhoea 0 0 1 (5) 0 4 (24) 4 (21) 14 13
Oral herpes 0 0 0 0 3 (18) 4 (21) 10 14
Cough 0 0 1 (5) 1 (5) 4 (24) 2 (11) 13 6
Vomiting 1 (5) 0 0 2 (10) 3 (18) 2 (11) 11 6
Pyrexia 2 (10) 1 (5) 0 0 2 (12) 2 (11) 7 6
Rhinitis allergic 2 (10) 0 0 0 3 (18) 1 (5) 11 3
Dermatitis infected 0 1 (5) 2 (10) 2 (10) 0 1 (5) 0 3
OLE, open-label extension; nP/100PY, number of patients with ≥1 event per 100 patient-years; SOC, Medical Dictionary for Regulatory
Activities (MedDRA) system organ class; HLT, MedDRA high level term; PT, MedDRA preferred term; URTI, upper respiratory tract infection.
aIncludes all TEAEs reported up to the first visit when patients switched from weight-based dosing (2 mg kg1 or 4 mg kg1) to a fixed dose
regimen of 300 mg every 4 weeks. bThe number of patients with ≥ 1 TEAE per PY was defined as the number of patients with ≥ 1 TEAE
divided by total PY among patients in the study and at risk of an initial occurrence of the event; for patients with an event, the number of
PY was calculated up to the date of the first event; for patients without an event, it corresponded to the duration of the TEAE period. cIn-
cludes MedDRA PTs angular cheilitis, bacterial disease carrier, dermatitis infected, folliculitis, hordeolum, molluscum contagiosum, skin bac-
terial infection, staphylococcal skin infections and tinea infections. dIncludes MedDRA PTs herpes simplex, nasal herpes and oral herpes.
eIncludes MedDRA PTs injection-site oedema, injection-site haemorrhage, injection-site induration, injection-site irritation, injection-site mass
and injection-site swelling. fIncludes MedDRA PTs conjunctivitis, conjunctivitis allergic and conjunctivitis bacterial. gIncludes all MedDRA PTs
reported in ≥ 10% or ≥ 20% of patients in any treatment group of the phase IIa study or phase III OLE, respectively.
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Rescue medication
Five adolescents in the phase IIa study received rescue medica-
tion (four in the 2 mg kg1 dupilumab group and one in the
4 mg kg1 dupilumab group). Only one adolescent in the 2
mg kg1 group of the OLE received rescue treatment (sys-
temic corticosteroids).
Discussion
The phase IIa study and phase III OLE were the earliest studies
of dupilumab in adolescents to characterize its PK and long-
term safety and efficacy profile. The results from these studies
support use of dupilumab for the long-term management of
moderate-to-severe AD in adolescents. The PK profile was
characterized by nonlinear, target-mediated kinetics, consistent
with the profile in adults with moderate-to-severe AD.31 A
better assessment of attainment of steady state was obtained in
the OLE, where the 2 mg kg1 and 4 mg kg1 weekly regi-
mens led to a mean steady-state Ctrough similar to that reported
for the 300 mg every 2 weeks (75 mg L1) and weekly
(180 mg L1) regimens in adults, respectively.32 The trend
toward linear, dose-proportional kinetics of Ctrough between
the 2 mg kg1 and 4 mg kg1 weekly regimens in the OLE
provides support for selection of these phase III dose levels
and exposures and is indicative of saturating the target-
mediated pathway (i.e. the minimum condition needed for
optimal efficacy). The slightly greater-than-dose-proportional-
ity in Ctrough between the 2 mg kg
1 and 4 mg kg1 weekly
regimens suggests that there is likely a greater proportion of
patients achieving saturation of the target-mediated pathway at
4 mg kg1 vs. 2 mg kg1.
No new safety signals were observed in adolescents with
moderate-to-severe AD, compared with the known safety pro-
file of dupilumab in adults with moderate-to-severe AD.17–21
Although 4 mg kg1 dupilumab was associated with more
TEAEs than 2 mg kg1 during the phase IIa study, the inci-
dence of TEAEs was comparable between the two treatment
groups in the OLE. None of the SAEs observed in either of the
studies was deemed to be related to dupilumab. Skin infections
were reported for both treatment groups, with a higher inci-
dence for the 4 mg kg1 dose in both studies. However, stud-
ies in adults showed that dupilumab is associated with reduced
risk of skin infections vs. placebo and does not increase overall
infection rates vs. placebo in patients with AD.17–21 Injection-
site reactions and conjunctivitis AEs were mild to moderate
and did not lead to treatment discontinuation. The most com-
mon AEs were AD exacerbation and infected AD. AD exacerba-
tion may have resulted from insufficient treatment, as it
occurred several weeks after receiving a single dose of dupilu-
mab in the phase IIa study. The OLE showed that the safety
profile associated with long-term treatment (up to 52 weeks)
with dupilumab in adolescents is consistent with that seen with
short-term treatment (up to 16 weeks).
The phase IIa study provided preliminary evidence of dupi-
lumab efficacy in adolescents, with early improvements inT
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EASI and Peak Pruritus NRS after a single dose of dupilumab.
There was no clear dose response, as the two dose regimens
provided comparable response on most end points, except for
IGA 0 or 1; a higher proportion of adolescents achieved IGA
of 0 or 1 in the 4 mg kg1 cohort than in the 2 mg kg1
cohort. Most of these patients continued to receive dupilumab
in the OLE, and improvements were maintained for up to 52
weeks of treatment. With continuous treatment in the OLE,
there was a further reduction in disease severity on multiple
domains, including intensity and extent of signs, symptoms
(e.g. pruritus) and QoL.
Although the effect of dupilumab in atopic/allergic comor-
bidities was not analysed in these studies, dupilumab-
mediated improvements were observed in comorbid type 2
conditions like asthma, allergic rhinitis and food/aero-allergies
in the phase III adolescent study.33 This, together with the
high rates of atopic/allergic comorbidities in both adolescent
patient populations, support the underlying role of IL-4/IL-
13-driven type 2 inflammation in these diseases. Although the
safety and efficacy results are generally consistent with previ-
ous studies of dupilumab in adults with AD, they should be
interpreted with caution as the populations presented here
were small. Moreover, there was no placebo arm, and the
studies were open-label. Patients were not randomized to the
two dupilumab dose regimens at the start of the phase IIa
study. As noted, concomitant use of TCS was allowed, but not
standardized, in the phase IIa study and the OLE, which may
have confounded efficacy measurements. In addition, patients
receiving repeated dosing had already been exposed to dupilu-
mab (i.e. were not treatment na€ıve), which may have influ-
enced outcomes in both studies. As the number of patients
included in the study was small and efficacy was not the pri-
mary objective, P-values vs. baseline were not reported.
Finally, it should be noted that although the exposure with
the 2 mg kg1 weekly regimen was comparable to that in
adolescents treated with the every-two-weeks regimen in the
phase III study (Simpson et al. submitted for publication), the
regimens used in the phase IIa and OLE studies were not the
actual currently approved every-two-weeks regimen in the
adolescent patient population.
In summary, in adolescents with moderate-to-severe AD,
dupilumab exhibited a PK profile similar to adults. Findings
from the OLE support the long-term safety and efficacy of dupi-
lumab in adolescents with moderate-to-severe AD, extending
and reinforcing the findings from a randomized, double-blind,
placebo-controlled phase III trial (NCT03054428) and
recently published case series (Simpson et al. submitted for
publication).33,34
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